LUCDライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:49):

Stats
本日の出来高	72 295.00
平均出来高	174 998
時価総額	33.70M
EPS	$-0.250 ( 2024-03-26 )
次の収益日	( $-0.270 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.550
ATR14	$0.00500 (0.72%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	White Debra	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sparks Ronald M	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Lapidus Stanley	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Cox James L	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sokolov Jacque J	Buy	150 000	Employee stock option (right to buy)

INSIDER POWER
33.35
Last 57 transactions
Buy: 13 183 319 \| Sell: 4 158 892

ボリューム相関

長: 0.02 (neutral)

短: 0.59 (weak)

Signal:(56.002) Neutral

Lucid Diagnostics Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Lucid Diagnostics Inc. 相関 - 通貨/商品

0.54
( weak )

0.56
( weak )

0.00
( neutral )

0.87
( strong )

-0.49
( neutral )

Lucid Diagnostics Inc. 財務諸表

Annual	2023
収益:	$2.43M
総利益:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2023
収益:	$2.43M
総利益:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2022
収益:	$377 000
総利益:	$-3.24M (-858.62 %)
EPS:	$-1.550

FY	2021
収益:	$500 000
総利益:	$-85 000.00 (-17.00 %)
EPS:	$-1.510

Financial Reports:

No articles found.

Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.